Cartridge and Pen Materials Market Size & Share 2026-2035

Cartridge and Pen Materials Market Size

The Cartridge and Pen Materials Market was valued at USD 2.32 billion in 2025, is expected to reach USD 2.51 billion in 2026, and is projected to expand at a 7.3% CAGR (2026–2035) to reach USD 4.69 billion by 2035. The market covers the demand-side first-sale value of pharmaceutical-grade glass, polymer, metal, and elastomer components supplied to pharmaceutical manufacturers, CMOs/CDMOs, and device assemblers for injectable cartridges and pen systems.

The Cartridge and Pen Materials Market is being reshaped by the migration of chronic and specialty therapies toward self-administered injection formats. Demand is increasingly tied to recurring use of insulin, GLP-1 receptor agonists, biologics, and specialty injectables, while material selection is becoming more consequential as drug formulations, container-closure requirements, and device-performance expectations become more stringent.

Cartridge and Pen Materials Market Trends, Growth Drivers & GMI Forecast Outlook

Demand is moving toward higher-specification cartridge and pen configurations as self-injected GLP-1 therapies, biologics, and chronic-care drugs require reliable containment, dose delivery, and patient usability. Market expansion depends not only on therapy adoption, but also on suppliers' ability to qualify materials and add validated manufacturing capacity.

Key Drivers

Diabetes remains the market's foundational volume pool because a transition from vial-and-syringe regimens to pen-based delivery creates recurring demand for cartridge barrels, closures, and associated injection components. The commercial effect extends beyond new diagnoses: conversion of existing insulin users to pen delivery broadens the installed base of consumers requiring replenishment components over time.

GLP-1 therapies add a more acute source of demand because treatment uptake is closely connected to pen-system consumption. These products also tend to require carefully specified cartridge, closure, and mechanism combinations, allowing suppliers with qualified component platforms to participate in both unit-volume growth and product-mix improvement.

The shift of biologics toward subcutaneous administration further increases the value placed on drug compatibility, breakage resistance, dose accuracy, and container integrity. Qualification cycles can be lengthy, but once a material configuration is accepted for a drug-device combination, the resulting supplier relationship is difficult to displace with a lower-specification alternative.

Key Restraints

*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*

Annex 1 conversion is a structural constraint rather than a temporary operating issue. Suppliers must dedicate engineering, analytical, cleanroom, packaging, and regulatory resources to compliance upgrades, which can delay the addition of dedicated capacity for emerging pen platforms even when customer demand is visible.

Precision moulding, automated assembly, and cartridge-component validation also require a longer response cycle than pharmaceutical demand changes. A new therapy can scale rapidly following reimbursement or label expansion, whereas component suppliers must install equipment, qualify processes, validate performance, and meet customer-specific quality requirements before additional supply becomes commercially usable.

Borosilicate tubing adds another layer of supply-chain sensitivity because cartridge production depends on tightly controlled dimensional, chemical, and quality characteristics. Alternative materials can reduce exposure in selected applications, but switching a marketed drug-device platform requires compatibility work and regulatory discipline, limiting the pace at which substitution can solve short-term shortages.

Cartridge and Pen Materials Market Segment Analysis

By Material Type

Glass Materials generated USD 750 million in 2025 and are expected to account for 30.5% of the market in 2035. Glass remains the reference containment material for many insulin, GLP-1, and biologic products because of its established pharmaceutical history, chemical resistance, and broad regulatory familiarity. Its mix position is being challenged selectively rather than broadly, as advanced polymer alternatives gain relevance where breakage resistance, optical performance, or formulation compatibility are decisive.

Polymer Materials represented 24.6% of the market in 2025 and are projected to reach USD 1.27 billion by 2035. Polymer adoption is concentrated in applications where container performance must be tailored to complex formulations or patient-use conditions. COC and COP materials are particularly relevant to advanced biologics platforms, while engineered polymers also support the dimensional precision and design flexibility required in pen bodies and delivery mechanisms.

Metal Components are projected to reach USD 683 million by 2035 and are expected to expand at a 6.6% CAGR (2026–2035). Metal remains essential in needle assemblies, springs, crimping elements, and precision mechanical interfaces. However, the category faces relative mix pressure as manufacturers pursue lighter, more integrated polymer and composite assemblies for portions of the pen architecture that do not require metal's mechanical properties.

Elastomer Components generated USD 640 million in 2025 and are expected to represent 28.0% of the market in 2035. Elastomers remain indispensable to cartridge sealing, plunger movement, and container-closure integrity. Their strategic value is rising with the use of barrier films and coating technologies that help manage extractables, particulate performance, and compatibility risks for sensitive biologic and GLP-1 formulations.

By Product Type

Cartridge Systems generated USD 1.30 billion in 2025 and are projected to reach USD 2.65 billion by 2035. Cartridge systems capture the direct effect of injectable-drug volume growth because every compatible pen format requires a qualified primary container. The category benefits from the progression of therapies from clinic-administered to self-injected formats, particularly where drug makers seek consistent dose delivery and patient convenience.

Pen Components generated USD 812 million in 2025 and are projected to reach USD 1.74 billion by 2035. Pen components are gaining importance as dose delivery becomes more differentiated. Mechanisms, needle assemblies, actuation systems, and patient-facing features are increasingly designed around usability, dosing precision, and connectivity, raising the value of engineering capability alongside manufacturing scale.

Closure & Sealing Systems generated USD 208 million in 2025 and are expected to grow at a 3.9% CAGR (2026–2035). This category is supported by recurring cartridge demand, but its growth profile is tempered by mature penetration and pricing discipline in more standardized elements. Value creation is therefore concentrated in high-performance coatings, validated closure systems, and quality tiers that reduce risk for sensitive injectable formulations.

By Application

Diabetes Management generated USD 1.22 billion in 2025 and is expected to represent 51.8% of the market in 2035. Diabetes management remains the central demand base because insulin delivery creates recurring cartridge and needle consumption across a broad patient population. GLP-1 therapies are changing the mix within this application by lifting demand for higher-specification materials and more sophisticated pen configurations.

Biologics & Biosimilars Delivery represented 25.2% of the market in 2025 and is projected to reach USD 1.22 billion by 2035. Biologic self-injection is increasing the importance of formulation compatibility, container integrity, and patient usability. Biosimilar commercialization can broaden access without necessarily lowering component specifications, supporting continued demand for validated cartridge and closure combinations.

Specialty Therapeutics are projected to reach USD 907 million by 2035 and are expected to expand at a 7.9% CAGR (2026–2035). Specialty applications benefit as subcutaneous delivery becomes more viable for therapies historically administered in clinical settings. Oncology, autoimmune, and rare-disease platforms often require differentiated device performance, creating opportunities for suppliers that can support complex drug-device development and qualification work.

Others represented 3.9% of the market in 2025 and are expected to account for 3.0% in 2035. This category includes mature and emerging uses with more limited contribution to overall demand. Its long-term relevance depends on whether new injectable modalities achieve commercially scalable self-administration formats rather than remaining confined to early-stage or niche clinical applications.

Cartridge and Pen Materials Market Regional Analysis

North America Cartridge and Pen Materials Market Analysis

The Cartridge and Pen Materials Market in North America generated USD 905 million in 2025 and is expected to represent 35.9% of the market in 2035. North America remains the leading value market because of advanced injectable-therapy uptake, established reimbursement channels, and the concentration of pharmaceutical procurement, fill-finish, and device-development activity. Demand is weighted toward premium cartridge, closure, and mechanism systems that support branded GLP-1 drugs, biologics, and specialty therapies.

United States

The Cartridge and Pen Materials Market in the United States generated USD 810 million in 2025 and is projected to reach USD 1.51 billion by 2035. The United States combines deep demand for chronic-care pens with a high concentration of drug developers, device firms, and specialized manufacturing partners. Its market profile favors suppliers able to support combination-product requirements, human-factors expectations, and premium material qualification for increasingly complex self-injection therapies.

Canada

Canada represented 10.5% of North American market revenue in 2025 and is expected to expand at a 6.7% CAGR (2026–2035). Canadian demand is supported by established insulin and biologics access, with biosimilar availability creating additional opportunities for pen-based treatment formats. Procurement and reimbursement structures reward dependable supply and validated component performance, supporting steady demand for established delivery platforms.

Europe Cartridge and Pen Materials Market Analysis

Europe represented 29.0% of the market in 2025 and is projected to reach USD 1.29 billion by 2035. Europe combines significant pharmaceutical demand with a concentrated supplier base spanning glass, elastomer, cartridge, and drug-delivery systems. Compliance conversion under Annex 1 is reinforcing demand for higher-quality components while increasing the strategic importance of suppliers with established sterile manufacturing and qualification capabilities.

Germany

Germany generated USD 112 million in 2025 and is projected to reach USD 215 million by 2035. Germany's importance extends beyond domestic therapy consumption because it is a manufacturing and technology center for pharmaceutical glass and injectable-drug packaging. Its production ecosystem supports demand for high-specification cartridge materials and makes supply continuity, regulatory compliance, and technical qualification central commercial considerations.

United Kingdom

The United Kingdom represented 14.1% of European market revenue in 2025 and is expected to grow at a 6.6% CAGR (2026–2035). Demand in the United Kingdom is supported by structured access to insulin, biologics, and other pen-delivered therapies. The market's growth depends on the ability of manufacturers and healthcare channels to convert broader treatment adoption into sustained use of qualified cartridge and device systems.

France

France is projected to reach USD 192 million by 2035 and represented 14.9% of European market revenue in 2025. France benefits from strong pharmaceutical consumption, broad reimbursement mechanisms, and a substantial domestic life-sciences base. Its pen-materials demand is supported by established diabetes care and the continued migration of selected biologic therapies toward patient-administered formats.

Italy

Italy generated USD 82 million in 2025 and is expected to represent 12.1% of European market revenue in 2035. Italy's market benefits from established insulin-pen use, increasing biologics penetration, and proximity to specialized pharmaceutical packaging and device manufacturing. Local production capabilities support demand for validated components, particularly where regional fill-finish activity requires close supplier coordination.

Spain

Spain represented 10.1% of European market revenue in 2025 and is projected to reach USD 130 million by 2035. Spain's universal-care environment supports broad use of pen-based diabetes treatment and a growing base of self-administered biologic therapies. Pricing controls can restrain value realization, increasing the relevance of suppliers that can provide quality, supply assurance, and efficient component configurations.

Asia Pacific Cartridge and Pen Materials Market Analysis

Asia Pacific is projected to reach USD 1.25 billion by 2035 and is expected to expand at an 8.9% CAGR (2026–2035). Asia Pacific is the principal volume-growth region, supported by a large diabetes population, expanding pharmaceutical manufacturing, and increasing access to advanced injectable therapies. Its demand profile spans both high-volume, cost-conscious insulin formats and premium biologic or GLP-1 platforms, creating a broad range of material and component requirements.

China

China generated USD 130 million in 2025 and is projected to reach USD 310 million by 2035. China's market is supported by domestic insulin manufacturing, growing interest in GLP-1 platforms, and investment in localized pharmaceutical production. Suppliers that can meet Chinese quality requirements while supporting cost-effective scale are positioned to benefit from the expansion of local cartridge and pen programs.

Japan

Japan represented 20.3% of Asia Pacific market revenue in 2025 and is expected to account for 15.6% in 2035. Japan is a mature pen-delivery market with demanding quality expectations and strong incumbent supplier relationships. While volume growth is more measured than in emerging Asian markets, high material standards and recurring replacement demand support a resilient premium-component market.

India

India is projected to reach USD 235 million by 2035 and is expected to expand at an 11.1% CAGR (2026–2035). India offers a combination of expanding diabetes care, developing biologics capacity, and increasing interest in locally supported pharmaceutical supply chains. The market's potential is tied to broader access to pen-based therapies and the ability of domestic and multinational suppliers to provide qualified components at scalable cost levels.

South Korea

South Korea generated USD 55 million in 2025 and is expected to represent 8.4% of Asia Pacific market revenue in 2035. South Korea's advanced biologics and CDMO ecosystem supports demand for high-specification cartridge and pen assemblies. Its export-oriented biopharmaceutical industry requires component quality that can satisfy international market requirements, strengthening the case for premium materials and tightly controlled supply relationships.

Latin America Cartridge and Pen Materials Market Analysis

Latin America represented 5.5% of the market in 2025 and is projected to reach USD 285 million by 2035. Latin American demand is being shaped by institutional insulin programs, broader access to diabetes treatment, and the gradual expansion of regional pharmaceutical manufacturing. Market development varies materially by country, making procurement systems, reimbursement pathways, and local regulatory requirements important determinants of component demand.

Brazil

Brazil generated USD 52 million in 2025 and is projected to reach USD 117 million by 2035. Brazil is the region's principal market because public-health procurement provides a durable base for insulin delivery, while private-sector biologics use adds higher-value demand. Regulatory compliance and domestic pharmaceutical activity create opportunities for suppliers able to provide validated products with reliable local or regional support.

Mexico

Mexico represented 23.6% of Latin American market revenue in 2025 and is expected to grow at an 8.8% CAGR (2026–2035). Mexico benefits from growing private healthcare demand and its connection to North American manufacturing networks. Its longer-term opportunity includes not only domestic therapy adoption, but also possible expansion of contract manufacturing and component-assembly activity serving cross-border pharmaceutical supply chains.

Middle East & Africa Cartridge and Pen Materials Market Analysis

Middle East & Africa generated USD 83 million in 2025 and is expected to expand at a 7.9% CAGR (2026–2035). Middle East & Africa is supported by high diabetes prevalence in several Gulf markets, government-funded treatment programs, and expanding access to specialty medicines. The region remains comparatively small in value terms, but its demand is increasingly shaped by formal procurement programs and healthcare investment rather than solely by private-sector consumption.

Saudi Arabia

Saudi Arabia generated USD 22 million in 2025 and is projected to reach USD 50 million by 2035. Saudi Arabia's demand is anchored in diabetes care and government-supported healthcare delivery. Pharmaceutical localization initiatives could deepen future demand for cartridge and pen components by increasing the role of domestic manufacturing and fill-finish operations.

UAE

The UAE represented 21.7% of Middle East & Africa market revenue in 2025 and is expected to grow at a 7.8% CAGR (2026–2035). The UAE functions as a regional distribution and specialty-care hub, supporting demand for advanced injectable therapies and premium delivery systems. Its private healthcare infrastructure and alignment with international product standards favor validated, higher-specification cartridge and pen configurations.

Cartridge and Pen Materials Market Share & Competitive Landscape

The Cartridge and Pen Materials Market share structure is moderately concentrated, with the leading five suppliers collectively accounting for approximately 49.8% of the market in 2025. Competition remains fragmented below the top tier because glass, elastomer, polymer, cartridge, mechanism, and integrated-device categories each require specialized manufacturing, intellectual property, quality systems, and customer qualification capabilities.

SCHOTT Pharma AG & Co. KGaA held a 13.2% market share in 2025. SCHOTT Pharma's positioning is rooted in pharmaceutical-grade glass, ready-to-use cartridge systems, and technical expertise in containment solutions for insulin, GLP-1, and biologic applications. Its competitive strength lies in combining glass-material capability with stringent quality control and commercialization support for complex injectable formats.

Gerresheimer AG held a 10.8% market share in 2025. Gerresheimer benefits from its broad primary-packaging footprint and its ability to integrate glass production, cartridge conversion, and pharmaceutical customer support. The company is well positioned where customers prioritize supply security, scale, and qualified packaging platforms for increasingly complex injectable-drug portfolios.

Stevanato Group S.p.A. held a 9.2% market share in 2025. Stevanato competes across glass primary packaging, polymer systems, and drug-delivery devices, giving it exposure to multiple stages of the self-injection value chain. This portfolio breadth supports collaboration with pharmaceutical customers that seek more integrated cartridge-and-device development rather than discrete component procurement.

West Pharmaceutical Services is a key supplier of premium elastomer closures and delivery-system components. Its position is strengthened by demand for coated and high-performance stopper platforms that address extractables, particulate control, and container-closure integrity in sensitive injectable formulations.

Ypsomed is an important specialist in pen bodies, injection mechanisms, and self-injection platforms. The company's strategic relevance is tied to the growing need for dependable, patient-oriented delivery systems that can accommodate more complex dosing and therapeutic formats.

Nipro provides cartridge and closure capabilities that make it an important alternative source within the global pharmaceutical glass and injectable-component supply chain. Its presence is especially relevant to pharmaceutical customers seeking broader supplier diversification across Asian and international manufacturing networks.

SHL Medical, BD, Aptar Pharma, Datwyler, Nolato, Terumo, Haselmeier, Phillips-Medisize, Nemera, Credence MedSystems, Shandong Pharma Glass, and other specialized suppliers compete through differentiated strengths in precision moulding, needle systems, elastomer technologies, connected-device features, combination-product development, contract manufacturing, and regional production support.

Recent Industry Developments

SCHOTT Pharma expands sterile ready-to-use cartridge production in Hungary: In June 2026, SCHOTT Pharma announced an investment of more than EUR 100 million in sterile ready-to-use cartridge production at its Lukácsháza facility. The project is intended to support biologics, GLP-1 medicines, insulin, and hormone therapies through integrated washing and steam-sterilization capabilities ^{[5]SCHOTT Pharma AG & Co. KGaA. “SCHOTT Pharma invests in sterile cartridge production in Hungary.” manufacturingchemist.com}.

Ypsomed and BD expand large-volume biologics collaboration: In January 2026, Ypsomed and BD announced an expanded partnership around a large-volume glass prefillable syringe and autoinjector combination platform. The collaboration addresses the increasing need for self-administration systems designed for higher-volume biologic formulations ^{[6]Ypsomed AG. “Ypsomed and BD expand partnership to advance self-injection systems for large-volume biologics.” ypsomed.com}.